| |
|
|
|
|
|
|
|||
|
PHAGOCYTES
From the Departments of Pediatrics, Internal Medicine,
and Experimental Pathology, the Huntsman Cancer Institute, and the
Program in Human Molecular Biology and Genetics, the University of Utah
School of Medicine, Salt Lake City, UT.
Leukocyte adhesion deficiency type I (LAD-1) is a disorder
associated with severe and recurrent bacterial infections, impaired extravascular targeting and accumulation of myeloid leukocytes, altered
wound healing, and significant morbidity that is caused by absent or
greatly diminished surface expression of integrins of the
To eliminate invasive microrganisms, leukocytes
must adhere to endothelial cells and migrate from the blood through the
endothelial barrier and the extracellular matrix to sites of infection
and tissue injury. The ability of neutrophils (polymorphonuclear
leukocytes [PMNs]) and other classes of leukocytes to reach the
extravascular milieu is dependent on the coordinate actions of adhesion
molecules on their surfaces and on endothelial cells.1-4
These critical tethering molecules include integrins.5 The
principal class of integrins on neutrophils and other leukocytes is
composed of a common Neutrophils and other leukocytes circulate in a quiescent nonadhesive
state but can rapidly become adhesive when activated by signaling
molecules that include bacterial and complement peptides, chemokines,
lipid factors, and other inflammatory mediators.7,10-12 Cellular activation causes heterodimers to become competent to recognize their ligands on other cells and in matrix structures, a
process that is termed "inside-out signaling" or "integrin
activation"1,13,14 and that involves altered conformation
and/or clustering of the integrins.6,7,15,16 Cytoskeletal
proteins and intracellular transduction molecules interact directly or
indirectly with the cytoplasmic domains of integrins of different
classes and are involved in their conversion from the quiescent to the
adhesive state.13,14,17 The specific biochemical
mechanisms that mediate inside-out signaling of integrins are, however,
not completely defined.14,17 In addition to their adhesive
functions, integrins can modulate cellular behavior by transmitting
signals from the exterior to the inside of the cell, a process referred
to as "outside-in signaling."13,18,19
Human syndromes resulting from deficiency or impaired function of
integrins and other adhesion molecules have contributed critical
insights into their biologic roles.7 They are also important, albeit rare, clinical problems. Leukocyte adhesion deficiency type I (LAD-1) is an autosomal recessive disorder
characterized by recurrent infections that are frequently
life-threatening, impaired extravascular accumulation of PMNs and
monocytes that is manifested clinically as lack of pus formation, and
dysregulated wound healing that causes late separation of the umbilical
cord and other abnormalities of tissue repair in many
subjects.6,20,21 LAD-1 is distinguished from LAD-2, which
is caused by a defect in synthesis of fucosylated glycoconjugates that
are required for the functions of selectin ligands,22-24
by impaired Recently 2 subjects with "variant" forms of LAD-1 have been
reported.29,30 The surface levels of Antibodies
Assay of surface expression of cell adhesion molecules
Assays of neutrophil 2 function on stimulated neutrophils with assays of adhesion, aggregation, and chemotaxis. The 2
integrin-dependent adhesion to human umbilical vein endothelial cells
(HUVECs) and to immobilized matrix proteins was assayed as previously
described.33-35 Matrix proteins were added to wells at
concentrations from 30 to 60 µg/mL, allowed to adhere at 4°C
overnight, blocked with 1% human serum albumin (HSA) for 2 hours at
37°C, and washed with Hanks Balanced Salt Solution (HBSS;
Biowhittaker; Walkersville, MD) before use. HUVECs were isolated with
collagenase and grown in a primary culture on gelatin-treated
wells.36 Neutrophils were isolated and labeled with 0.0185 MBq (0.5 µCi) 111Indium per 106
cells.36 Adhesion was induced with activating agonists
that trigger inside-out signaling of 2
integrins34 or with divalent cation
substitution.37-39 We have previously shown that adhesion under these conditions is specifically mediated by 2
integrins.34,35 For divalent cation substitution,
neutrophils were suspended in HBSS, free of Ca++ and
Mg2+, containing 1 mM EDTA, washed one time, and
then resuspended in 1 mM Mn2+.38 The mAb KIM
185 (10 µg/mL) was also used to stimulate 2-dependent adhesion of PMNs.40,41 Aggregation assays were performed
with 5.5 × 106 neutrophils per milliliter and were
measured by the increase in light transmission in an aggregometer
(Payton Scientific, Buffalo, NY).36 Chemotaxis was
measured as previously described.42
Analysis of other leukocyte functions Oxygen radical generation.
Superoxide anion generation was measured as the fraction of
cytochrome c reduction inhibited by superoxide
dismutase.33 Briefly, 2.2 × 106 neutrophils
were added to the well of a 96-well plate in a final volume of 20 mL
HBSS containing 1% HSA and cytochrome c (0.5 mg/mL) with or
without superoxide dismutase (0.1 mg/mL). Neutrophils were stimulated
with phorbol myristate acetate (PMA, 10 Intracellular calcium.
Cells were loaded with the calcium-sensitive fluorescent dyes Indo-1
(neutrophils) or Fura-2 AM (EBV-transformed lymphoblasts) by incubation with 10 Actin polymerization. Neutrophils at 5 × 106 cells/mL were combined with 8% formaldehyde, 150 µg/mL lysophosphatidylcholine, and 50 µg/mL FITC-conjugated phalloidin (2.5 µg/mL, Sigma Chemical) for 4 hours on ice and then washed with phosphate-buffered saline (PBS). Filamentous actin was detected by flow cytometry as previously described.45 Preparation of transformed lymphoblasts Lymphocytes from the patient or from control subjects were suspended at 2 × 106 cells/m in RPMI 1640 (Biowhittaker, Walkersville, MD) with 2 mM L-glutamine, 20% fetal calf serum (Hyclone, Logan, UT), and 0.4 µg/mL cyclosporin A,46 and plated at 2 × 105 cells per well into a 96-well flat-bottomed plate. The 100-µL filtered (0.45 µm) supernatant from a culture of the EBV-shedding line B958 (American Tissue Culture Collection, Rockville, MD) was added to each well.47 The cells were fed as needed with media containing 10% fetal calf serum and 0.2 µg/mL cyclosporin A. Wells were examined for growth, and cells were transferred first to 24-well plates and later to flasks. Cyclosporin A was discontinued after 3 weeks. The transformed lymphoblasts were then maintained in RPMI-1640 with 5% fetal calf serum, 5% fetal clone 1 (Hyclone), and 2 mM glutamine with antibiotic supplementation (penicillin-streptomycin and amphotericin B). The patient-derived EBV-transformed lymphoblasts (LADV cells) and age-matched control EBV-transformed lymphoblasts (control lymphoblasts) were used in subsequent experiments.Transformed lymphoblast adhesion assay EBV-transformed lymphoblasts were labeled with 0.185 MBq (5 µCi) 111Indium per 106 cells using the same protocol as previously described for neutrophils.36 The labeled lymphoblasts were then added to wells coated with immobilized ligands (details in figure legends) and allowed to settle for 60 minutes at 4°C, and the adhesion assay was performed as described for neutrophils (above). In other experiments, lymphoblast adhesion was measured by using fluorescent labeling as previously described.48,49 Briefly, 96-well microtiter plates (Costar, Cambridge, MA) were incubated with the indicated concentrations of fibronectin or a recombinant ICAM-1 IgG chimera (a gift from Joel Hayflick and Pat Hoffman, Icos, Bothell, WA) overnight at 4°C and then blocked with HBSS/2.5% bovine serum albumin (BSA). Transformed lymphoblasts were labeled with 2 µg/mL Calcein-AM (Molecular Probes), washed according to the manufacturer's protocol, added to wells (5 × 104 cells per well with appropriate stimuli in a final volume of 100 µL), and stimulated with agonists as indicated. The lymphoblasts were then allowed to settle for 60 minutes at 4°C, warmed to 37°C for the indicated times, and nonadherent cells were removed by washing. Adherent cells were quantified by using a fluorescence plate reader (Cytofluor 2300, Millipore, Bedford, MA). The fraction of adherent cells was assessed as the level of fluorescence in the well after washing, divided by total input fluorescence, and multiplied by 100. In experiments examining divalent cation substitution, the incubations were performed as described previously for primary neutrophils, except that EDTA was not added.Lymphocyte aggregation assay EBV-transformed lymphoblasts were resuspended at a concentration of 0.85 × 106 cells/mL with PMA at final 10 7 M concentration in the aggregometer, using the same
protocol used for PMNs (previously described). PMN aggregation was
assayed in parallel as a positive control.
Western immunoblotting EBV-transformed lymphoblasts at 20 × 106 cells/mL were lysed in RIPA buffer with 1% Nonidet P-40 (Sigma Chemical) according to the manufacturer's instructions (Santa Cruz Biotechnology, Santa Cruz, CA) and centrifuged at 15 000g for 20 minutes at 4°C. For 2 integrin detection, the
lysates (1 mL) were collected and 10 µg anti- 2 mAb,
60.3, was added for 1 hour at 4°C. Protein A-Agarose (20 µL, Santa
Cruz Biotechnology) was added, and the lysates were kept at 4°C, with
mixing overnight. The agarose pellet was washed 4 times with RIPA
buffer and then boiled with 40 µL electrophoresis sample buffer for
90 seconds. Western blot analysis was performed as previously
described50 using goat antimouse IgG conjugated to
horseradish peroxidase as the secondary antibody (BioSource
International, Camarillo, CA) and ECL Western blot detection reagents
(Amersham Life Science, Arlington Heights, IL). For 1
subunit detection, 6 × 106 of the patient-derived
EBV-transformed lymphoblasts (LADV cells), control EBV-transformed
lymphoblasts, and Jurkat T cells were lysed in 100 µL RIPA buffer,
passed through an 18-gauge needle 3 times, placed in boiling water for
2 minutes, and stored at 20°C. Lysates in nonreducing buffer were
then run on a 7.5% SDS-PAGE gel, and Western blot analysis was
performed as described previously using the anti- 1 mAb
MAB 13 as the primary antibody.
Sequence analysis of 1 integrin in 3 overlapping fragments. The 5' end
fragment was amplified by using the following primers: adapter primer 1 (supplied from Marathon cDNA Amplification Kit), 5'-CCA TCC TAA TAC GAC
TCA CTA TAG GGC and 5'-GTA GCT AAA TGG GGT GGT GCA GTT CTG. The second
fragment was amplified with the following primers: 5'-CAG CTA AGC TCA
GGA ACC CTT GCA C and 5'-CTG CAC GCG CCA CAC TCA AAT GTC. The 3' end
fragment was amplified using the following primers: 5'-CCA AAG CGA AGG
CAT CCC TGA AAG and 5'-CAG TGT TGT GGG ATT TGC ACG GGC AG. For
2 sequence, 3 pairs of primers were designed to cover
the entire coding region in overlapping fragments. The 5' end fragment
was amplified from single strand cDNA using the primers: 5'-CCA GCA CAC
CGA GGG ACA TGC TG and 5'-CGT GAC GTT GCG CCA GCC GAT TTC. The second
fragment and the 3' end fragment were amplified from double-strand cDNA
by using the following 2 pairs of primers respectively: 5'-CTG GAC GCC
ATG ATG CAG GTC GC and 5'-CTG GCC GTT GTA GCG CTC ACA GTT G, and
5'-CAA CTC CAT CAT CTG CTC AGG GCT G and 5'-CTG ACG GCC TTG TCT
TCA CCA AGT G. A "touchdown" polymerase chain reaction (PCR) was
carried out in PE GeneAmp Systems 2400, according to the instructions
from the Marathon cDNA Amplification Kit. The PCR products were ligated into the PCR2.1 vector (Invitrogen) using the manufacturer's
instructions. Individual white colonies were screened, and the plasmid
DNAs were analyzed in the University of Utah core sequencing facility. Multiple clones were sequenced for each fragment.
Clinical features of the affected infant indicated a unique syndrome of leukocyte adhesion deficiency The patient, a male infant, first presented at 3 weeks of age with anemia, thrombocytopenia, leukocytosis (35-45 × 109 cells/L), and a "blueberry muffin" rash. He was delivered after a full-term pregnancy, and his size was appropriate for gestational age. There was no family history of recurrent infection, immune deficiency, or consanguinity. Maternal screening was negative for infections, including human immunodeficiency virus and hepatitis B. At the time of presentation, assay of the infant's serum for IgM antibodies directed against cytomegalovirus, rubella, toxoplasmosis, EBV, parvovirus, human herpesvirus 6, and herpes simplex 1 and 2 were all negative. Viral cultures were also negative. In the fourth through seventh months of life, he had several bacterial infections: an infected urachal duct cyst (cultures grew Bacteroides vulgaris, Enterococcus faecalis, Enterococcus avium, and hemolytic streptococcus), pneumonia (B vulgaris and Candida
albicans were cultured from the bronchoalveolar lavage fluid),
nonhemolytic streptococcal septicemia, and a perirectal ulceration and
cellulitis without pus collection that grew Escherichia coli
on culture. He also had episodes of pneumonia caused by respiratory
syncitial and parainfluenza viruses, oral candidiasis, and a C
albicans urinary tract infection, and pneumonia caused by
Pneumocystis carinii. The leukocytosis found at the time of
presentation persisted until bone marrow transplant, and leukocyte
counts as high as 96 × 109 cells/L were recorded.
Because the persistent leukocytosis and recurrent severe infections
suggested the possibility of LAD-1, analysis of cell surface
2 integrins on the infant's circulating neutrophils was
performed. Normal levels were detected (Table 1 and data not shown). Studies of
adhesive function of the child's circulating neutrophils were then
performed as described in detail below. A biopsy of the "blueberry
muffin" rash showed dermal erythropoiesis. At 6 weeks of age, the
infant had normal quantitative IgG, IgA, and IgM levels. CD4 and CD8 T
lymphocyte numbers were normal. At 6 months of age, the T-lymphocyte
function was assessed, and there were positive responses in vitro to
the mitogens phytohemagglutinin, concanavalin A, and pokeweed and to
specific antigens (tetanus and candida) after immunization and
infection, respectively.
In addition to the leukocyte abnormalities, the child was anemic and thrombocytopenic from the time of presentation. Later, the patient had hepatosplenomegaly and mucosal bleeding develop coincident with omphalitis caused by Bacteroides and an enterococcal species. In vitro analysis of the patient's platelet function demonstrated that platelet suspensions did not aggregate in response to collagen, adenosine diphosphate, arachidonic acid, or ristocetin, and there was absent clot retraction. The template bleeding time was more than 15 minutes. A bone marrow biopsy at 1 month of age revealed that the marrow was markedly hypocellular, but there were no dysplastic changes. A bone marrow biopsy at 7 months of age revealed trilineage dysplasia most pronounced in the granulocytic elements. Cytogenetic analysis was normal; specifically, monosomy 7 and deletion of 5q, 8q, or 17q alterations that are associated with myeloid malignancies,51,52 were not detected. At 8 months, the patient underwent successful bone marrow transplantation using an HLA-matched sibling donor. Three years after engraftment, he has no clinical or laboratory evidence for an immune deficit. A recent circulating leukocyte count was 10.7 × 109 cells/L with an absolute neutrophil count of 3.9 × 109 cells/L. There have been no further severe bacterial or viral infections. Primary neutrophils isolated from the subject expressed
2 integrin marker, M 2
(Table 1). In addition, the surface levels of M and
2 increased 1.5-fold in response to stimulation of the
PMNs with PMA. Therefore, we assessed the adhesive functions of the
patient's neutrophils by using in vitro assays. There was dramatic
impairment of adhesion to gelatin, which depends on inside-out signaling of 2 integrins,34,35,53 when
freshly isolated PMNs from the subject were stimulated with
N-formyl-met-leu-phe (fMLP) and compared with neutrophils from a
control subject (Figure 1). The
impairment in adhesion was similar to that seen previously in studies
of neutrophils with absent surface expression of 2 integrins from a patient with LAD-1, and when neutrophils from control
subjects were treated with function-blocking anti- 2
integrin antibodies.33-35 A similar impairment in adhesion
was seen when the patient's PMNs were stimulated with
platelet-activating factor (PAF), which is recognized by a
G-protein-linked receptor on the leukocyte surface that is different
from the receptor for fMLP,54 and when the neutrophils
were treated with the receptor-independent agonists PMA and calcium
ionophore A23187 (not shown). Stimulated adhesion of the patient's
neutrophils to fibrinogen, a ligand for
M 2 and
X 2,6 and to monolayers of
cultured human endothelial cells was also dramatically impaired
compared with that of control PMNs (Figure 1 and data not shown),
although there was a small increase in adhesion in some
experiments.
The patient's neutrophils were found to express PSGL-1, the fucosylated leukocyte counterligand that recognizes the endothelial tethering molecules P-selectin and E-selectin,55 with cell surface levels that were greater than those on neutrophils from a control subject studied in parallel (Table 1). We assessed the function of PSGL-1 on the patient's PMNs and found that they adhered normally to purified, immobilized P-selectin in adhesion assays conducted as previously described33 (not shown). The adhesion was inhibited by a specific monoclonal antibody against P-selectin. This indicated that the PSGL-1 detected on the surfaces of the PMNs was functional and that the infant did not have LAD-2.22,25 In a second experiment that confirmed this conclusion, the patient's neutrophils adhered to purified immobilized E-selectin, and this was inhibited by an anti-E-selectin antibody (not shown). We then examined the performance of the patient's neutrophils in 2 additional assays that measure
In parallel studies, we found that intracellular calcium transients in response to fMLP or calcium ionophore A23187,33 polymerization of actin in response to PMA as measured with FITC-conjugated phalloidin,45 superoxide generation in response to PMA,33 and shedding of L-selectin in response to PMA57 were each intact in the patient's neutrophils when compared with the PMNs from control subjects (data not shown). In addition, the patient's PMNs polarized in solution in response to fMLP (not shown). These experiments excluded a generalized defect in surface receptor function, intracellular signaling cascades, and signal-dependent effector functions of the PMNs from the subject. We then asked whether the extracellular domains of integrins on the
infant's PMNs could recognize ligands in the presence of the exogenous
cation Mn2+, a manipulation that eliminates the requirement
for cellular activation and inside-out signaling via cytoplasmic
pathways,37,38,58 or in response to an antibody that can
induce ligand recognition. By using the protocols described
previously,38 we found that, when Mn2+ was
substituted for Ca++ and Mg2+ in a suspension
of the patient's neutrophils, there was increased adhesiveness in 2 of
3 experiments. The increase in adhesion of the infant's PMNs to
immobilized ligand was 2- to 6-fold compared with a 4- to 8-fold
increase in adhesion of control neutrophils (data not shown). In a
second experiment, we used KIM 185, a function-perturbing mAb against
Transformed lymphoblasts from the affected subject have defective
adhesive functions mediated by 2 and L, the dominant
subunit paired with 2 on lymphocytes and
lymphoblasts,60 were expressed at levels equal to or
greater than those found on the surfaces of control lymphoblastoid
cells from age-matched subjects (Figure 5). In addition, the integrin
1 chain and the 4 and 5
subunits were expressed on LADV lymphoblasts at levels equivalent to
those on control lymphoblastoid cells (Figure 5). LADV cells and
age-matched control lymphoblastoid cells each shed 50% or more of
their surface L-selectin when treated with 10 7 M
PMA,61 and the intracellular calcium transients triggered by treatment with calcium ionophore were similar in both LADV cells and
control lymphoblasts (not shown). In addition, LADV cells
demonstrated a calcium transient in response to concanavalin A (not
shown). These features indicated that the LADV cells display surface
integrins at the expected density and perform signal-dependent functions and therefore could be used as surrogate cells in additional studies of the adhesive defects in the patient's leukocytes.
LADV cells did not aggregate when treated with PMA, whereas control
lymphoblastoid cells aggregated as expected (not shown). In a second
assay of their adhesive function, we examined the binding of LADV cells
to an immobilized ICAM-1/IgG chimera. ICAM-1 is a ligand for
We then asked whether the defect was specific for
Inside-out signaling triggers clustering of integrins and consequent
increased avidity for ligands, in addition to triggering increased
affinity as a result of altered conformation.15,64-66 Release of integrins from cytoskeletal constraints by treating cells
with cytochalasins also induces increased avidity and consequent adhesion under some conditions.65,66 We found that
treatment of LADV cells with low concentrations of cytochalasin D
enhanced their adhesion to fibronectin in response to PMA, but did not correct the defect in adhesion in comparison to control lymphoblastoid cells (Figure 8). This result indicates
that cytoskeletal interactions of
The adhesion defects in LADV cells are not a result of altered
structures of 2 protein from LADV cells demonstrated a band of the
expected molecular size, 95 kd (Figure
9A). Similarly, analysis of the
1 protein from LADV cells revealed a band at the
expected size, 110 kd, on a nonreduced gel (Figure 9B). Further
analysis of 2 cloned from LADV cells revealed that the
cDNA sequence was normal in all clones examined (2 each) for fragments
2 and 3, and 4 of 5 clones for the 5' proximal fragment (fragment 1, details in "Patient, materials, and methods"). The sequences of the
1 cDNA from LADV and control lymphoblastoid cells (2 clones each) were identical, but in each case, there was a histidine at
position 112 rather than threonine as in the original published
sequence.67-69 This polymorphism has previously been
reported in human cDNA clones (Hillier et al, GenBank accession
AA112739, 1995). Position 112 is outside of the known 1
ligand-binding regions.70 In addition, the control
EBV-transformed lymphoblasts exhibited adhesion to fibronectin (Figure
7), indicating that this polymorphism generated a functional protein.
Thus, structural alterations in 1 and 2 do not account for the adhesion defects in the LADV cells and appear
not to account for the abnormalities of integrin-dependent adhesion in
primary leukocytes from the patient.
The clinical presentation and laboratory studies of the child
described in this report document a syndrome of variant leukocyte adhesion deficiency in which surface levels of integrins were normal or
increased, but integrin-dependent adhesive functions of circulating
leukocytes were impaired. Furthermore, analysis of the LADV cell line
developed from lymphocytes collected from the affected infant before
bone marrow transplantation indicates a defect in inside-out signaling
of Dramatically reduced expression of The first of the previously identified patients with variant LAD-1 had
clinical features consistent with the mild form of LAD-1 but normal
levels of The second individual with a variant LAD-1 syndrome to be
reported also had features that differ from the child we describe here,
including a mild LAD-1-like phenotype, compound mutations yielding 2 abnormal Analysis of the LADV lines of EBV-transformed lymphoblasts from the
affected patient demonstrated defective In contrast to the result with LADV cells, leukocytes from both of the
other patients with variant LAD-1 had normal Although this is the first human syndrome associated with
impaired signaling of both The mechanisms of inside-out signaling of integrins leading to
increases in their affinity and avidity remain
elusive.7,14,17 Naturally occurring alterations in
integrins of specific classes and in their regulatory pathways in
syndromes that now include Glanzmann thrombasthenia,90
LAD-1,21 and variant LAD-1 provide important insights into
the functions and control of these ubiquitous tethering molecules. The
LAD-1 variant syndrome of the infant we describe here and the in vitro
behavior of cells from the subject are unique, and further analysis of
the LADV cell line may yield additional useful information regarding
the mechanisms by which
We thank Michaeline Bunting, Aaron Pontsler, and Diana Stafforini for assisting with sequence analysis, Jim Jenkins for the development of the Epstein-Barr virus-transformed cell lines and Donelle Benson for technical assistance. We also thank Patrick Beatty, Dan Simon, Rodger McEver, Thomas Tedder, Joel Hayflick, and Pat Hoffman for providing us with antibodies and reagents. Lastly, we thank John Bohnsack and members of our laboratories for useful discussions and other contributions, Diana Lim for graphics, and Michelle Bills and Leona Montoya for the preparation of this manuscript.
Submitted December 28, 1999; accepted October 2, 2000.
Supported by the National Institutes of Health (KO8 HL03799, HL02726, HL44525, P5O HL50153) and by an Established Investigator Award from the American Heart Association (9640261N).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Guy A. Zimmerman, Program in Human Molecular, Biology and Genetics, Eccles Institute of Human Genetics, 15 North 2030 East, Suite 4220, University of Utah Health Sciences Center, Salt Lake City, UT 84112.
1. Hynes RO, Lander AD. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell. 1992;68:303-322[CrossRef][Medline] [Order article via Infotrieve]. 2. Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today. 1992;13:93-100[CrossRef][Medline] [Order article via Infotrieve].
3.
Carlos TM, Harlan JM.
Leukocyte-endothelial adhesion molecules.
Blood.
1994;84:2068-2101 4. McEver RP. Interactions of leukocytes with the vessel wall. In: Loscalzo J,Schaffer AI, eds. Thrombosis and Hemorrhage. 2nd ed. Philadelphia, PA: Williams and Wilkins; 1998:321-336. 5. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25[CrossRef][Medline] [Order article via Infotrieve]. 6. Kishimoto TK, Baldwin ET, Anderson DC. The role of beta2 integrins in inflammation. In: Gallin JI,Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1999:537-569.
7.
Harris ES, Prescott SM, McIntyre TM, Zimmerman GA.
Minireview: the leukocyte integrins.
J Biol Chem.
2000;275:23409-23412 8. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314[CrossRef][Medline] [Order article via Infotrieve]. 9. Stewart M, Thiel M, Hogg N. Leukocyte integrins. Curr Opin Cell Biol. 1995;7:690-696[CrossRef][Medline] [Order article via Infotrieve]. 10. Ebnet K, Kaldjian EP, Anderson AO, Shaw S. Orchestrated information transfer underlying leukocyte endothelial interactions. Annu Rev Immunol. 1996;14:155-177[CrossRef][Medline] [Order article via Infotrieve]. 11. Shimizu Y, Hunt SW 3rd. Regulating integrin-mediated adhesion: one more function for PI 3-kinase? Immunol Today. 1996;17:565-573[CrossRef][Medline] [Order article via Infotrieve]. 12. Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions. J Clin Invest. 1996;98:1699-1702[Medline] [Order article via Infotrieve]. 13. Williams MJ, Hughes PE, O'Toole TE, Ginsberg MH. The inner world of cell adhesion: integrin cytoplasmic domains. Trends Cell Biol. 1994;4:109-112[CrossRef][Medline] [Order article via Infotrieve]. 14. Hughes PE, Pfaff M. Integrin affinity modulation. Trends Cell Biol. 1998;8:359-364[CrossRef][Medline] [Order article via Infotrieve]. 15. Stewart M, Hogg N. Regulation of leukocyte integrin function: affinity vs. avidity. J Cell Biochem. 1996;61:554-561[CrossRef][Medline] [Order article via Infotrieve]. 16. Gahmberg CG. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr Opin Cell Biol. 1997;9:643-650[CrossRef][Medline] [Order article via Infotrieve]. 17. Kolanus W, Seed B. Integrins and inside-out signal transduction: converging signals from PKC and PIP3. Curr Opin Cell Biol. 1997;9:725-731[CrossRef][Medline] [Order article via Infotrieve]. 18. Dedhar S, Hannigan GE. Integrin cytoplasmic interactions and bidirectional transmembrane signalling. Curr Opin Cell Biol. 1996;8:657-669[CrossRef][Medline] [Order article via Infotrieve]. 19. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol. 1994;4:506-517[CrossRef][Medline] [Order article via Infotrieve]. 20. Anderson DC, Schmalsteig FC, Finegold MJ, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. 1985;152:668-689[Medline] [Order article via Infotrieve]. 21. Anderson DC, Kishimoto TK, Smith CW. Leukocyte adhesion deficiency and other disorders of leukocyte adherence and motility. In: Scrivner CR,Beaudet AL,Sly WS, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 1995:3955-3994. 22. Karsan A, Cornejo CJ, Winn RK, et al. Leukocyte adhesion deficiency type II is a generalized defect of de novo GDP-fucose biosynthesis. J Clin Invest. 1998;101:2438-2445[Medline] [Order article via Infotrieve].
23.
Kansas G.
Selectins and their ligands: current concepts and controversies.
Blood.
1996;88:3259-3287 24. Varki A. Perspectives series: cell adhesion in vascular biology. Selectin ligands: will the real ones please stand up? J Clin Invest. 1997;99:158-162[Medline] [Order article via Infotrieve]. 25. Etzioni A, Frydman M, Pollack S, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med. 1992;327:1789-1792[Medline] [Order article via Infotrieve]. 26. von Adrian UH, Berger EM, Ramezani L, et al. In vivo behavior of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndrome. J Clin Invest. 1993;91:2893-2897. 27. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med. 1987;38:175-194[CrossRef][Medline] [Order article via Infotrieve]. 28. Harlan JM. Leukocyte adhesion deficiency syndrome: insights into the molecular basis of leukocyte emigration. Clin Immunol Immunopathol. 1993;67:S16-S24[CrossRef][Medline] [Order article via Infotrieve]. 29. Kuijpers TW, Van Lier RA, Hamann D, et al. Leukocyte adhesion deficiency type 1 (LAD-1)/variant: a novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J Clin Invest. 1997;100:1725-1733[Medline] [Order article via Infotrieve]. 30. Hogg N, Stewart MP, Scarth SL, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest. 1999;103:97-106[Medline] [Order article via Infotrieve]. 31. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66[Abstract]. 32. Mobley JL, Ennis E, Shimizu Y. Isolation and characterization of cell lines with genetically distinct mutations downstream of protein kinase C that result in defective activation-dependent regulation of T cell integrin function. J Immunol. 1996;156:948-956[Abstract]. 33. Lorant DE, Topham MK, Whatley RE, et al. Inflammatory roles of P-selectin. J Clin Invest. 1993;92:559-570. 34. Zimmerman GA, McIntyre TM. Neutrophil adherence to human endothelium in vitro occurs by CDw18 (Mo1, MAC-1/LFA-1/GP 150,95) glycoprotein-dependent and -independent mechanisms. J Clin Invest. 1988;81:531-537.
35.
Bohnsack JF, Akiyama SK, Damsky CH, Knape WA, Zimmerman GA.
Human neutrophil adherence to laminin in vitro: evidence for a distinct neutrophil integrin receptor for laminin.
J Exp Med.
1990;171:1221-1237 36. Zimmerman GA, McIntyre TM, Prescott SM. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest. 1985;76:2235-2246.
37.
Dransfield I, Cabanas C, Craig A, Hogg N.
Divalent cation regulation of the function of the leukocyte integrin LFA-1.
J Cell Biol.
1992;116:219-226 38. Bohnsack JF, Zhou XN. Divalent cation substitution reveals CD18- and very late antigen-dependent pathways that mediate human neutrophil adherence to fibronectin. J Immunol. 1992;149:1340-1347[Abstract].
39.
Bohnsack JF, Chang J.
Activation of beta 1 integrin fibronectin receptors on HL60 cells after granulocytic differentiation.
Blood.
1994;83:543-552 40. Andrew D, Shock A, Ball E, Ortlepp S, Bell J, Robinson M. KIM185, a monoclonal antibody to CD18 which induces a change in the conformation of CD18 and promotes both LFA-1- and CR3-dependent adhesion. Eur J Immunol. 1993;23:2217-2222[Medline] [Order article via Infotrieve]. 41. Ortlepp S, Stephens PE, Hogg N, Figdor CG, Robinson MK. Antibodies that activate beta 2 integrins can generate different ligand binding states. Eur J Immunol. 1995;25:637-643[Medline] [Order article via Infotrieve]. 42. Hill HR, Ochs HD, Quie PG, et al. Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent "cold" staphylococcal abscesses. Lancet. 1974;2:617-619[Medline] [Order article via Infotrieve]. 43. Elstad MR, Parker CJ, Cowley FS, et al. CD11b/CD18 integrin and a beta-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes. J Immunol. 1994;152:220-230[Abstract].
44.
Marathe GK, Davies SS, Harrison KA, et al.
Inflammatory PAF-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines.
J Biol Chem.
1999;274:28395-28404
45.
Feldhaus MJ, Kessel JM, Zimmerman GA, McIntyre TM.
Engagement of ICAM-3 activates polymorphonuclear leukocytes: aggregation without degranulation or beta 2 integrin recruitment.
J Immunol.
1998;161:6280-6287 46. Beatty PR, Krams SM, Esquivel CO, Martinez OM. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation. 1998;65:1248-1255[CrossRef][Medline] [Order article via Infotrieve].
47.
Fujinami RS, Sun X, Howell JM, Jenkin JC, Burns JB.
Modulation of immune system function by measles virus infection: role of soluble factor and direct infection.
J Virol.
1998;72:9421-9427
48.
Romzek NC, Harris ES, Dell CL, et al.
Use of a beta1 integrin-deficient human T cell to identify beta1 integrin cytoplasmic domain sequences critical for integrin function.
Mol Biol Cell.
1998;9:2715-2727 49. Mobley J, Romzek N, Shimizu Y. Integrin activation in lymphocyte adhesion. In: Weir D,Herzenberg L,Blackwell C, eds. Handbook of Experimental Immunology. London, England: Blackwell Scientific; 1995:1-68.
50.
Weyrich AS, Dixon DA, Pabla R, et al.
Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets.
Proc Natl Acad Sci U S A.
1998;95:5556-5561
51.
Johnson EJ, Scherer SW, Osborne L, et al.
Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia.
Blood.
1996;87:3579-3586
52.
Heaney ML, Golde DW.
Myelodysplasia.
N Engl J Med.
1999;340:1649-1660
53.
Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM.
Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor.
J Biol Chem.
1991;266:11104-11110 54. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 1994;12:593-633[CrossRef][Medline] [Order article via Infotrieve]. 55. McEver RP, Cummings RD. Cell adhesion in vascular biology: role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 1997;100:485-491[Medline] [Order article via Infotrieve].
56.
Rothlein R, Springer TA.
The requirement for lymphocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester.
J Exp Med.
1986;163:1132-1149
57.
Kishimoto TK, Jutila MA, Berg EL, Butcher EC.
Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors.
Science.
1989;245:1238-1241
58.
Labadia ME, Jeanfavre DD, Caviness GO, Morelock MM.
Molecular regulation of the interaction between leukocyte function-associated antigen-1 and soluble ICAM-1 by divalent metal cations.
J Immunol.
1998;161:836-842 59. Hibbs ML, Wardlaw AJ, Stacker SA, et al. Transfection of cells from patients with leukocyte adhesion deficiency with an integrin beta subunit (CD18) restores lymphocyte function-associated antigen-1 expression and function. J Clin Invest. 1990;85:674-681. 60. Rincon J, Prieto J, Patarroyo M. Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells. Int J Cancer. 1992;51:452-458[Medline] [Order article via Infotrieve].
61.
Tominaga T, Sugie K, Hirata M, et al.
Inhibition of PMA-induced, LFA-1-dependent lymphocyte aggregation by ADP ribosylation of the small molecular weight GTP binding protein, rho.
J Cell Biol.
1993;120:1529-1537 62. Hemler ME, Sanchez-Madrid F, Flotte TJ, et al. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol. 1984;132:3011-3018[Abstract].
63.
Weber C, Alon R, Moser B, Springer TA.
Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis.
J Cell Biol.
1996;134:1063-1073
64.
Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME.
Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration.
Mol Biol Cell.
1998;9:2751-2765 65. Kucik DF, Dustin ML, Miller JM, Brown EJ. Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. J Clin Invest. 1996;97:2139-2144[Medline] [Order article via Infotrieve].
66.
Stewart MP, McDowall A, Hogg N.
LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain.
J Cell Biol.
1998;140:699-707
67.
Argraves WS, Suzuki S, Arai H, Thompson K, Pierschbacher MD, Ruoslahti E.
Amino acid sequence of the human fibronectin receptor.
J Cell Biol.
1987;105:1183-1190 68. Shih DT, Boettiger D, Buck CA. Epitopes of adhesion-perturbing monoclonal antibodies map within a predicted alpha-helical domain of the integrin beta 1 subunit. J Cell Sci. 1997;110:2619-2628[Abstract]. 69. Tuckwell DS, Humphries MJ. A structure prediction for the ligand-binding region of the integrin beta subunit: evidence for the presence of a von Willebrand factor A domain. FEBS Lett. 1997;400:297-303[CrossRef][Medline] [Order article via Infotrieve].
70.
Puzon-McLaughlin W, Takada Y.
Critical residues for ligand binding in an I domain-like structure of the integrin beta1 subunit.
J Biol Chem.
1996;271:20438-20443
71.
Hughes PE, Diaz-Gonzalez F, Leong L, et al.
Breaking the integrin hinge: a defined structural constraint regulates integrin signaling.
J Biol Chem.
1996;271:6571-6574 72. Humphries MJ. Integrin activation: the link between ligand binding and signal transduction. Curr Opin Cell Biol. 1996;8:532-640. 73. Lee JO, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell. 1995;80:631-638[CrossRef][Medline] [Order article via Infotrieve]. 74. Bergelson JM, Hemler ME. Integrin-ligand binding: do integrins use a 'MIDAS touch' to grasp an Asp? Curr Biol. 1995;5:615-617[CrossRef][Medline] [Order article via Infotrieve]. 75. Loftus JC, Liddington RC. Cell adhesion in vascular biology: new insights into integrin-ligand interaction. J Clin Invest. 1997;99:2302-2306[Medline] [Order article via Infotrieve].
76.
Loftus JC, Smith JW, Ginsberg MH.
Integrin-mediated cell adhesion: the extracellular face.
J Biol Chem.
1994;269:25235-25238 77. Arnaiz-Villena A, Timon M, Rodriguez-Gallego C, et al. Human T-cell activation deficiencies. Immunol Today. 1992;13:259-265[CrossRef][Medline] [Order article via Infotrieve].
78.
Loike JD, Cao L, Budhu S, et al.
Differential regulation of b1 integrins by chemoattractants regulates neutrophil migration through fibrin.
J Cell Biol.
1999;144:1047-1056 79. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature. 1997;390:81-85[CrossRef][Medline] [Order article via Infotrieve].
80.
Lukashev ME, Sheppard D, Pytela R.
Disruption of integrin function and induction of tyrosine phosphorylation by the autonomously expressed beta 1 integrin cytoplasmic domain.
J Biol Chem.
1994;269:18311-18314
81.
Chen Y-P, O'Toole TE, Shipley T, et al.
"Inside-out" signal transduction inhibited by isolated integrin cytoplasmic domains.
J Biol Chem.
1994;269:18307-18310 82. Diaz-Gonzalez F, Forsyth J, Steiner B, Ginsberg MH. Trans-dominant inhibition of integrin function. Mol Biol Cell. 1996;7:1939-1951[Abstract].
83.
Baker EK, Tozer EC, Pfaff M, Shattil SJ, Loftus JC, Ginsberg MH.
A genetic analysis of integrin function: Glanzmann thrombasthenia in vitro.
Proc Natl Acad Sci U S A.
1997;94:1973-1978
84.
Balzac F, Retta SF, Albini A, et al.
Expression of beta 1B integrin isoform in CHO cells results in a dominant negative effect on cell adhesion and motility.
J Cell Biol.
1994;127:557-565
85.
Retta SF, Balzac F, Ferraris P, et al.
beta1-integrin cytoplasmic subdomains involved in dominant negative function.
Mol Biol Cell.
1998;9:715-731
86.
Sethi T, Ginsberg MH, Downward J, Hughes PE.
The small GTP-binding protein R-Ras can influence integrin activation by antagonizing a Ras/Raf-initiated integrin suppression pathway.
Mol Biol Cell.
1999;10:1799-1809
87.
Kerst JM, Sanders JB, Slaper-Cortenbach IC, et al.
Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way.
Blood.
1993;81:344-351 88. Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R. Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J Lab Clin Med. 1997;129:584-591[CrossRef][Medline] [Order article via Infotrieve].
89.
Verfaillie CM.
Adhesion receptors as regulators of the hematopoietic process.
Blood.
1998;92:2609-2612 90. Newman PJ, Poncz M. Inherited disorders of platelets. In: Scriver CR,Beaudet AL,Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:3335-3366.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
T. W. Kuijpers, E. van de Vijver, M. A. J. Weterman, M. de Boer, A. T. J. Tool, T. K. van den Berg, M. Moser, M. E. Jakobs, K. Seeger, O. Sanal, et al. LAD-1/variant syndrome is caused by mutations in FERMT3 Blood, May 7, 2009; 113(19): 4740 - 4746. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pasvolsky, S. W. Feigelson, S. S. Kilic, A. J. Simon, G. Tal-Lapidot, V. Grabovsky, J. R. Crittenden, N. Amariglio, M. Safran, A. M. Graybiel, et al. A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets J. Exp. Med., July 9, 2007; 204(7): 1571 - 1582. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Kuijpers, R. v. Bruggen, N. Kamerbeek, A. T. J. Tool, G. Hicsonmez, A. Gurgey, A. Karow, A. J. Verhoeven, K. Seeger, O. Sanal, et al. Natural history and early diagnosis of LAD-1/variant syndrome Blood, April 15, 2007; 109(8): 3529 - 3537. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Garrood, L. Lee, and C. Pitzalis Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways Rheumatology, March 1, 2006; 45(3): 250 - 260. [Full Text] [PDF] |
||||
![]() |
K. Yonekawa and J. M. Harlan Targeting leukocyte integrins in human diseases J. Leukoc. Biol., February 1, 2005; 77(2): 129 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hogg, M. Laschinger, K. Giles, and A. McDowall T-cell integrins: more than just sticking points J. Cell Sci., December 1, 2003; 116(23): 4695 - 4705. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Andrews and K. E. Sullivan Infections in Patients with Inherited Defects in Phagocytic Function Clin. Microbiol. Rev., October 1, 2003; 16(4): 597 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Alon, M. Aker, S. Feigelson, M. Sokolovsky-Eisenberg, D. E. Staunton, G. Cinamon, V. Grabovsky, R. Shamri, and A. Etzioni A novel genetic leukocyte adhesion deficiency in subsecond triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow Blood, June 1, 2003; 101(11): 4437 - 4445. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Zimmerman Two by two: The pairings of P-selectin and P-selectin glycoprotein ligand 1 PNAS, August 28, 2001; 98(18): 10023 - 10024. [Full Text] [PDF] |
||||
![]() |
L.-L. HSIAO, F. DANGOND, T. YOSHIDA, R. HONG, R. V. JENSEN, J. MISRA, W. DILLON, K. F. LEE, K. E. CLARK, P. HAVERTY, et al. A compendium of gene expression in normal human tissues Physiol Genomics, December 21, 2001; 7(2): 97 - 104. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||